|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blackford AL, Canto MI, Dbouk M, Hruban
RH, Katona BW, Chak A, Brand RE, Syngal S, Farrell J, Kastrinos F,
et al: Pancreatic cancer surveillance and survival of high-risk
individuals. JAMA Oncol. 10:1087–1096. 2024. View Article : Google Scholar
|
|
3
|
Park W, Chawla A and O'Reilly EM:
Pancreatic cancer: A review. JAMA. 326:851–862. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peduzzi G, Archibugi L, Farinella R, de
Leon Pisani RP, Vodickova L, Vodicka P, Kraja B, Sainz J,
Bars-Cortina D, Daniel N, et al: The exposome and pancreatic
cancer, lifestyle and environmental risk factors for PDAC. Semin
Cancer Biol. 113:100–129. 2025. View Article : Google Scholar
|
|
5
|
Springfeld C, Ferrone CR, Katz MHG, Philip
PA, Hong TS, Hackert T, Büchler MW and Neoptolemos J: Neoadjuvant
therapy for pancreatic cancer. Nat Rev Clin Oncol. 20:318–337.
2023. View Article : Google Scholar
|
|
6
|
Hu ZI and O'Reilly EM: Therapeutic
developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol.
21:7–24. 2024. View Article : Google Scholar
|
|
7
|
Sang W, Zhou Y, Chen H, Yu C, Dai L, Liu
Z, Chen L, Fang Y, Ma P, Wu X, et al: Receptor-interacting protein
kinase 2 is an immunotherapy target in pancreatic cancer. Cancer
Discov. 14:326–347. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ullman NA, Burchard PR, Dunne RF and
Linehan DC: Immunologic strategies in pancreatic cancer: Making
cold tumors hot. J Clin Oncol. 40:2789–2805. 2022. View Article : Google Scholar
|
|
9
|
Zhao K, Huang J, Zhao Y, Wang S, Xu J and
Yin K: Targeting STING in cancer: Challenges and emerging
opportunities. Biochim Biophys Acta Rev Cancer. 1878:1889832023.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang B, Xu P and Ablasser A: Regulation
of the cGAS-STING pathway. Annu Rev Immunol. 43:667–692. 2025.
View Article : Google Scholar
|
|
11
|
Tani T, Mathsyaraja H, Campisi M, Li ZH,
Haratani K, Fahey CG, Ota K, Mahadevan NR, Shi Y, Saito S, et al:
TREX1 inactivation unleashes cancer cell STING-interferon signaling
and promotes antitumor immunity. Cancer Discov. 14:752–765. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo J, Wang S, Yang Q, Fu Q, Zhu C, Li T,
Yang S, Zhao Y, Guo R, Ben X, et al: γδ T Cell-mediated tumor
immunity is tightly regulated by STING and TGF-β signaling
pathways. Adv Sci (Weinh). 12:e24044322025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu X, Hogg GD, Zuo C, Borcherding NC,
Baer JM, Lander VE, Kang LI, Knolhoff BL, Ahmad F, Osterhout RE, et
al: Context-dependent activation of STING-interferon signaling by
CD11b agonists enhances anti-tumor immunity. Cancer Cell.
41:1073–1090.e12. 2023. View Article : Google Scholar
|
|
14
|
Tian X, Ai J, Tian X and Wei X: cGAS-STING
pathway agonists are promising vaccine adjuvants. Med Res Rev.
44:1768–1799. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X, Xu Z, Li T, Thakur A, Wen Y, Zhang
K, Liu Y, Liang Q, Liu W, Qin JJ and Yan Y:
Nanomaterial-encapsulated STING agonists for immune modulation in
cancer therapy. Biomark Res. 12:22024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chin EN, Sulpizio A and Lairson LL:
Targeting STING to promote antitumor immunity. Trends Cell Biol.
33:189–203. 2023. View Article : Google Scholar
|
|
17
|
Chen X, Meng F, Xu Y, Li T, Chen X and
Wang H: Chemically programmed STING-activating nano-liposomal
vesicles improve anticancer immunity. Nat Commun. 14:45842023.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dosta P, Cryer AM, Dion MZ, Shiraishi T,
Langston SP, Lok D, Wang J, Harrison S, Hatten T, Ganno ML, et al:
Investigation of the enhanced antitumour potency of STING agonist
after conjugation to polymer nanoparticles. Nat Nanotechnol.
18:1351–1363. 2023. View Article : Google Scholar
|
|
19
|
Wen Z, Sun F, Wang R, Wang W, Zhang H,
Yang F, Wang M, Wang Y and Li B: STING agonists: A range of eminent
mediators in cancer immunotherapy. Cell Signal. 134:1119142025.
View Article : Google Scholar
|
|
20
|
Ohara Y, Tang W, Liu H, Yang S, Dorsey TH,
Cawley H, Moreno P, Chari R, Guest MR, Azizian A, et al:
SERPINB3-MYC axis induces the basal-like/squamous subtype and
enhances disease progression in pancreatic cancer. Cell Rep.
42:1134342023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee M, Thomas AS, Lee SY, Cho YJ, Jung HS,
Yun WG, Han Y, Jang JY, Kluger MD and Kwon W: Reconsidering the
absence of extrapancreatic extension in T staging for pancreatic
adenocarcinoma in the AJCC (8th ed) staging manual using the
national cancer database. J Gastrointest Surg. 27:2484–2492. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kerschbaum-Gruber S, Kleinwächter A,
Popova K, Kneringer A, Appel LM, Stasny K, Röhrer A, Dias AB,
Benedum J, Walch L, et al: Cytosolic nucleic acid sensors and
interferon beta-1 activation drive radiation-induced anti-tumour
immune effects in human pancreatic cancer cells. Front Immunol.
15:12869422024. View Article : Google Scholar
|
|
24
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yin L, Wei J, Lu Z, Huang S, Gao H, Chen
J, Guo F, Tu M, Xiao B, Xi C, et al: Prevalence of germline
sequence variations among patients with pancreatic cancer in China.
JAMA Netw Open. 5:e21487212022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Larson NB, Oberg AL, Adjei AA and Wang L:
A clinician's guide to bioinformatics for next-generation
sequencing. J Thorac Oncol. 18:143–157. 2023. View Article : Google Scholar
|
|
27
|
Petralia F, Ma W, Yaron TM, Caruso FP,
Tignor N, Wang JM, Charytonowicz D, Johnson JL, Huntsman EM, Marino
GB, et al: Pan-cancer proteogenomics characterization of tumor
immunity. Cell. 187:1255–1277.e27. 2024. View Article : Google Scholar
|
|
28
|
Lv M, Chen M, Zhang R, Zhang W, Wang C,
Zhang Y, Wei X, Guan Y, Liu J, Feng K, et al: Manganese is critical
for antitumor immune responses via cGAS-STING and improves the
efficacy of clinical immunotherapy. Cell Res. 30:966–979. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li S, Mirlekar B, Johnson BM, Brickey WJ,
Wrobel JA, Yang N, Song D, Entwistle S, Tan X, Deng M, et al:
STING-induced regulatory B cells compromise NK function in cancer
immunity. Nature. 610:373–380. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Hubisz MJ, Earlie EM, Duran MA, Hong
C, Varela AA, Lettera E, Deyell M, Tavora B, Havel JJ, et al:
Non-cell-autonomous cancer progression from chromosomal
instability. Nature. 620:1080–1088. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jneid B, Bochnakian A, Hoffmann C, Delisle
F, Djacoto E, Sirven P, Denizeau J, Sedlik C, Gerber-Ferder Y,
Fiore F, et al: Selective STING stimulation in dendritic cells
primes antitumor T cell responses. Sci Immunol. 8:eabn66122023.
View Article : Google Scholar
|
|
32
|
Wang J, Li S, Wang M, Wang X, Chen S, Sun
Z, Ren X, Huang G, Sumer BD, Yan N, et al: STING licensing of type
I dendritic cells potentiates antitumor immunity. Sci Immunol.
9:eadj39452024. View Article : Google Scholar
|
|
33
|
Yang Y, Song J, Zhao H, Zhang H and Guo M:
Patients with dermatomyositis shared partially similar
transcriptome signature with COVID-19 infection. Autoimmunity.
56:22209842023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu QC, Tien YC, Shi YH, Chen S, Zhu YQ,
Huang XT, Huang CS, Zhao W and Yin XY: METTL3 promotes intrahepatic
cholangiocarcinoma progression by regulating IFIT2 expression in an
m6A-YTHDF2-dependent manner. Oncogene. 41:1622–1633.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou B, Liu Y, Ma H, Zhang B, Lu B, Li S,
Liu T, Qi Y, Wang Y, Zhang M, et al: Zdhhc1 deficiency mitigates
foam cell formation and atherosclerosis by inhibiting PI3K-Akt-mTOR
signaling pathway through facilitating the nuclear translocation of
p110α. Biochim Biophys Acta Mol Basis Dis. 1871:1675772025.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Le X, Mu J, Peng W, Tang J, Xiang Q, Tian
S, Feng Y, He S, Qiu Z, Ren G, et al: DNA methylation downregulated
ZDHHC1 suppresses tumor growth by altering cellular metabolism and
inducing oxidative/ER stress-mediated apoptosis and pyroptosis.
Theranostics. 10:9495–9511. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tang J, Peng W, Feng Y, Le X, Wang K,
Xiang Q, Li L, Wang Y, Xu C, Mu J, et al: Cancer cells escape p53′s
tumor suppression through ablation of ZDHHC1-mediated p53
palmitoylation. Oncogene. 40:5416–5426. 2021. View Article : Google Scholar : PubMed/NCBI
|
